Effects of high dose olmesartan medoxomil plus hydrochlorothiazide on blood pressure control in patients with grade 2 and grade 3 hypertension

Rump, L. C.; Girerd, Xavier; Sellin, Lorenz; Stegbauer, Johannes

doi:10.1038/jhh.2010.105

Cited by 18 publications

(12 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both were randomised, double-blind, parallel-group, multi-national, multi-centre studies conducted at 78 (Study 1) 11 and 92 (Study 2) 12 sites, respectively, in Europe (Czech Republic, Germany, Bulgaria, Spain, Ukraine, France, Poland, Belgium, the Netherlands, Russia and Slovakia).…”

Section: Methodsmentioning

confidence: 99%

“…The aim of this prespecified exploratory pooled analysis of data from two similarly designed clinical trials (Study 1: NCT00430508 11 ; Study 2: NCT00430950 12 ) was to compare the effects of OM/HCTZ combination therapy (20/ 12.5, 20/25, 40/12.5 and 40/25 mg) and OM 40 mg monotherapy on the secondary efficacy parameter of change from baseline to Week 8 in mean ambulatory BP (ABP) in patients with moderate-to-severe hypertension.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Olmesartan medoxomil combined with hydrochlorothiazide improves 24-hour blood pressure control in moderate-to-severe hypertension

Rosenbaum

Girerd

2012

Current Medical Research and Opinion

View full text Add to dashboard Cite

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Olmesartan medoxomil combined with hydrochlorothiazide improves 24-hour blood pressure control in moderate-to-severe hypertension

Rosenbaum

Girerd

2012

Current Medical Research and Opinion

View full text Add to dashboard Cite

show abstract

“…A recent European study investigated the safety and tolerability of OM/HCTZ in 1226 patients with stage 2 hypertension 24. Patients entered an 8-week open-label period and were treated with OM 40 mg per day.…”

Section: Efficacy Of Om and Hctz Combination Therapymentioning

confidence: 99%

Integrated control of hypertension by olmesartan medoxomil and hydrochlorothiazide and rationale for combination

Punzi¹

2011

IBPC

View full text Add to dashboard Cite

Hypertension affects nearly one-third of all individuals in the US, yet one-half of all treated patients achieve blood pressure (BP) controlled to recommended goals. The percentage of patients with uncontrolled BP is likely to be much higher when considering the number of patients who are not even aware of their hypertensive state. Elevated BP is associated with increased risks of cardiovascular events and end-organ damage. Antihypertensive monotherapy is not always sufficient to achieve BP goals, and thus more aggressive treatment regimens need to be considered. Antihypertensive combination therapy, which may improve tolerability, offers the benefit of targeting different mechanisms of action. Numerous outcomes studies support the use of a renin–angiotensin system inhibitor as a first-line choice in antihypertensive therapy. This review discusses the benefits of combination therapy with the angiotensin type II receptor blocker olmesartan medoxomil (OM) paired with the thiazide diuretic hydrochlorothiazide (HCTZ). The pharmacokinetic properties of OM will be reviewed in addition to efficacy studies that support OM + HCTZ combination therapy over other possible antihypertensive combinations. Finally, a rationale for choosing HCTZ over another diuretic, chlorthalidone, will also be discussed based on pharmacokinetic differences, clinical concerns, and trends in use.

show abstract

“…The combination of olmesartan and hydrochlorothiazide (HCTZ) in particular has been investigated in a number of clinical trials 6–11. These demonstrated that, at mean baseline BP values of 154–167 mmHg systolic and 88–103 mmHg diastolic, a combination of olmesartan 40 mg and HCTZ led to office BP reductions of 22–30 mmHg systolic and 10–22 mmHg diastolic.…”

Section: Introductionmentioning

confidence: 99%

Safety, tolerability, and efficacy of a fixed-dose combination of olmesartan 40 mg and hydrochlorothiazide 12.5/25 mg in daily practice

Bramlage

Zemmrich²,

Ketelhut³

et al. 2013

VHRM

View full text Add to dashboard Cite

BackgroundThe safety and efficacy of olmesartan 40 mg and hydrochlorothiazide (HCTZ) as a fixed-dose combination has been investigated in clinical trials leading to its approval. The aims of the present study were to confirm these data in an unselected patient population in daily practice and to determine the impact of physical activity on blood pressure control.MethodsIn a multicenter, noninterventional study, 3,333 patients with either insufficient blood pressure control on olmesartan 40 mg alone or on a fixed/free combination of olmesartan 40 mg and HCTZ 12.5/25 mg were primarily assessed for safety and tolerability of the fixed-dose combination of olmesartan 40 mg and HCTZ 12.5/25 mg at 24 ± 2 weeks. Secondary objectives were blood pressure reduction, treatment compliance, and impact of physical activity as measured by the sum of weekly energy costs.ResultsThe mean patient age was 63.2 ± 11.46 years, mean baseline blood pressure was 159.6 ± 15.28/93.5 ± 9.52 mmHg, and 70.9% had at least one additional cardiovascular risk factor. Adverse drug reactions were rare (n = 19), and no serious adverse drug reactions occurred. Compliance with drug therapy was at least sufficient in more than 99% of patients at the end of the study. Blood pressure at the last available visit was reduced by 26.1 ± 15.5/13.0 ± 10.1 mmHg versus baseline (P < 0.0001), but had reduced effectiveness in patients ≥75 years with diabetes or impaired renal function. In 69% of patients, blood pressure was normalized (<140/90 mmHg). No noteworthy differences in baseline characteristics or baseline blood pressure were found between patients with an activity level (sum of weekly energy costs) above or below the median of 9,460.6. A higher versus lower physical activity score had no impact on blood pressure reduction.ConclusionOur data confirm randomized trial data concerning safe and efficient blood pressure reduction using a fixed-dose combination of olmesartan 40 mg and HCTZ 12.5/25 mg in a large, unselected patient population, independent of physical activity level.

show abstract

Effects of high dose olmesartan medoxomil plus hydrochlorothiazide on blood pressure control in patients with grade 2 and grade 3 hypertension

Cited by 18 publications

References 32 publications

Olmesartan medoxomil combined with hydrochlorothiazide improves 24-hour blood pressure control in moderate-to-severe hypertension

Olmesartan medoxomil combined with hydrochlorothiazide improves 24-hour blood pressure control in moderate-to-severe hypertension

Integrated control of hypertension by olmesartan medoxomil and hydrochlorothiazide and rationale for combination

Safety, tolerability, and efficacy of a fixed-dose combination of olmesartan 40 mg and hydrochlorothiazide 12.5/25 mg in daily practice

Contact Info

Product

Resources

About